Lazard Asset Management’s ADC Therapeutics ADCT Stock Holding History

Lazard Asset Management’s Portfolio ADCT Stock Details ADCT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$985K	Buy	+262,595	New	+$1.04M	﹤0.01%	1172
2025 Q2	–	Sell	-1,203	Closed	-$1K	–	2279
2025 Q1	$1K	Sell	1,203 -4,615	-79%	-$7.84K	﹤0.01%	2220
2024 Q4	$11K	Buy	+5,818	New	+$15.2K	﹤0.01%	2100
2022 Q3	–	Sell	-16,098	Closed	-$127K	–	2283
2022 Q2	$127K	Buy	+16,098	New	+$152K	﹤0.01%	1420
2022 Q1	–	Sell	-1,863	Closed	-$37K	–	2307
2021 Q4	$37K	Buy	+1,863	New	+$44.9K	﹤0.01%	1856

Other funds holding ADCT

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

TCM

TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return

Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

EAM

Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return

NCM

Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Lazard Asset Management's ADCT Position: Q1 2026 in Review

Lazard Asset Management opened a new position in ADC Therapeutics (ADCT) in Q1 2026: 262,595 shares worth $985K. The stake represents ﹤0.01% of the portfolio and ranks #1172 among its holdings. This is a return to the name: Lazard Asset Management previously reported a position in ADCT as recently as Q1 2025.

Lazard Asset Management first reported a position in ADCT in Q4 2021 and has held it in 5 quarters since. 118 funds tracked by Wall St. Rank hold ADCT as of Q1 2026.

Lazard Asset Management held 262,595 shares of ADC Therapeutics worth $985K as of Q1 2026.
ADC Therapeutics was a new Lazard Asset Management position in Q1 2026.
ADC Therapeutics made up ﹤0.01% of Lazard Asset Management's portfolio in Q1 2026, its #1172 holding.
Lazard Asset Management first reported a position in ADC Therapeutics in Q4 2021 and has held it in 5 quarters since.
118 funds tracked by Wall St. Rank held ADC Therapeutics as of Q1 2026.

Based on Lazard Asset Management's 13F filing for Q1 2026, filed 15 May 2026.